Structural insights into the activation of MST3 by MO25

Youcef Mehellou a,*, Dario R. Alessia, Thomas J. Macartney a, Marta Szklarzb, Stefan Knappa, Jonathan M. Elkins b,*,

a MRC Protein Phosphorylation Unit, College of Life Sciences, University of Dundee, Dow Street, Dundee, DD1 5EH Scotland, UK
b Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK

A R T I C L E   I N F O
Article history:
Received 11 December 2012
Available online 4 January 2013

Keywords:
Protein kinase LKB1
Signal transduction
Protein structure and STE20

A B S T R A C T
The MO25 scaffolding protein operates as critical regulator of a number of STE20 family protein kinases (e.g. MST and SPAK isoforms) as well as pseudokinases (e.g. STRAD isoforms that play a critical role in activating the LKB1 tumour suppressor). To better understand how MO25 interacts and stimulates the activity of STE20 protein kinases, we determined the crystal structure of MST3 catalytic domain (residues 19–289) in complex with full length MO25b. The structure reveals an intricate web of interactions between MST3 and MO25 that function to stabilise the kinase domain in a closed, active, conformation even in the absence of ATP or an ATP-mimetic inhibitor. The binding mode of MO25 is reminiscent of the mechanism by which MO25 interacts with the pseudokinase STRADα. In particular we identified interface residues Tyr223 of MO25 and Glu58 and Ile71 of MST3 that when mutated prevent activation of MST3 by MO25. These data provide molecular understanding of the mechanism by which MO25 isoforms regulates the activity of STE20 family protein kinases.

© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.

1. Introduction

Mouse Protein-25 (MO25) is a highly conserved scaffolding protein originally discovered as a highly evolutionary conserved protein expressed at the early cleavage stage of mouse embryogenesis [1]. Mammals possess two closely related isoforms termed MO25x and MO25β, which share 79% sequence identity [2]. One of the most investigated roles of MO25x is as one of the core components of the LKB1 tumour suppressor complex that regulates proliferation, metabolism and polarity by phosphorylating and stimulating 14 AMPK family protein kinases [3]. The LKB1 kinase complex is a heterotrimer consisting of the protein kinase LKB bound to a catalytically inactive pseudokinase termed STRAD (of which there are two isoforms termed STRADα and STRADβ) and MO25 [4–6]. Association of LKB1 with MO25 and STRAD stimulates LKB1 protein kinase activity [2,4] and is essential for activation of AMPK family kinases [7,8].

The crystal structure of monomeric MO25α revealed that it consists of seven helical repeats arranged in a distinctive horseshoe shape distantly related to the Armadillo proteins with a concave surface aligned with highly conserved residues and a less conserved convex surface fold [9]. Subsequent work analysing the structure of the heterodimeric STRAD:MO25 [10] and the heterotrimeric LKB1:STRAD:MO25 [11] complexes showed that the concave surface of MO25 formed an intricate network of interactions with the α-helix of STRADα, reminiscent of the mechanism by which CDK2 interacts with cyclin A. MO25α acts to stabilise STRADα in an active conformation with an ordered T-loop that binds ATP and hence capable of binding to and activating LKB1 [10,11]. Activation of LKB1 is prevented by mutations that are predicted to destabilise the active conformation of STRADα namely those that prevent binding of STRADα to MO25x and ATP [11]. MO25α also stimulates LKB1 catalytic activity by binding directly with the T-loop of LKB1 and stabilises it in an active conformation [11].

Recent work has demonstrated that MO25 isoforms also interact with at least five distinct protein kinases that are related to STRADα/STRADβ and belong to the STE20 branch of mammalian kinases. These include SPAK and OSR1 that are important regulators of ion homeostasis and blood pressure [12] as well as MST3, MST4, YSK1 that control morphogenesis and polarity [13,14]. The catalytic activity of SPAK and OSR1 is stimulated over 100-fold by binding to MO25 isoforms, whereas MST3, MST4 and YSK1 are activated three- to four-fold. To learn more about the roles of MO25 in regulating STE20 protein kinases we have co-crystallised the catalytically active kinase domain of MST3 with MO25β. The structure reveals the intricate mechanism by which MO25β binds to MST3 and enables the construction of mutants that prevent activation of MST3 by MO25β.
2. Materials and methods

2.1. Reagents

Tissue-culture reagents were from Life Technologies. P81 phospho-cellulose paper was from Whatman and \( \gamma^{32P} \)-ATP was from Perkin Elmer. Myelin basic protein was from Sigma.

2.2. Expression and purification of MST3 and MO25\( ^{b} \) complex for crystallisation

MST3 and MO25\( ^{b} \) clones were transformed into E. coli BL21 (DE3) competent cells containing the pRARE2 plasmid from the commercial Rosetta strain, and the transformants were used to inoculate 50 ml of Luria–Bertani (LB) medium containing 50 \( \mu \)g/ml kanamycin (MST3) or 100 \( \mu \)g/ml ampicillin (MO25\( ^{b} \)) with the addition of 34 \( \mu \)g/ml chloramphenicol. These cultures were incubated overnight at 37 °C. For each protein, 3 × 10 ml of the overnight culture was used to inoculate 3 × 1 l of LB medium with 40 \( \mu \)g/ml kanamycin or 80 \( \mu \)g/ml ampicillin and grown at 37 °C until an OD\textsubscript{600} of 0.4–0.5 was reached. The temperature was then reduced to 20 °C. When the OD600 reached 0.6, expression was induced by addition of 0.5 mM IPTG, Expression was continued overnight. The cells were harvested by centrifugation. The MST3 cells were resuspended in Binding Buffer. The MO25\( ^{b} \) cells were resuspended in Buffer 1. The resuspended cells were frozen until further use.

For purification the cells were thawed and lysed by sonication on ice. PEI (polyethyleneimine) was added to a final concentration of 0.15% and the cell debris and precipitated DNA were spun down. MST3 was purified by passing the supernatant through a gravity column of 5 ml Glutathione-Sepharose (GE Healthcare). The resin was washed with 50 ml of Binding Buffer containing 1 M NaCl and 40 mM imidazole. 50 ml of Binding Buffer containing 60 mM imidazole before the protein was eluted with 25 ml of Binding Buffer containing 250 mM imidazole. The eluted protein was further purified by gel filtration chromatography using an S200 16/60 column pre-equilibrated in 20 mM Tris pH 7.5, 200 mM NaCl, 0.5 mM TCEP. MO25\( ^{b} \) was purified by passing the supernatant through a gravity column of 5 ml Glutathione-Sepharose (GE Healthcare). The resin was washed with 6x 10 ml of Buffer 1 and 6x 10 ml of Buffer 2. Precission protease was added to the resin and incubated overnight. The MO25\( ^{b} \) protein was then eluted with 50 ml of Buffer 2.

The MST3 protein was concentrated to 2.4 mg/ml and the MO25\( ^{b} \) protein was concentrated to 7.8 mg/ml. The concentrated proteins were mixed in an equimolar ratio and injected onto an S200 16/60 gel filtration column pre-equilibrated in 20 mM Tris pH 7.5, 200 mM NaCl, 0.5 mM TCEP. Fractions containing the protein complex were pooled and concentrated to 9.7 mg/ml. Protein identities were confirmed by mass spectrometry under denaturing conditions (MST3: expected 33257 Da, observed 33257 Da; MO25\( ^{b} \): expected 39225 Da, observed 39225 Da).

2.3. Structure determination

Crystals were obtained using the sitting drop vapour diffusion method at 4 °C. The protein (9.7 mg/ml) was mixed 1:1 with a reservoir solution containing 0.2 M Na/KPO4, 10% PEG 3350, 10% Ethylene Glycol in a drop size of 150 nl. Crystals were cryoprotected by transfer into reservoir solution containing 25% ethylene glycol. Crystals were then flash-frozen in liquid nitrogen and diffraction data were collected at Diamond beamline I04-1. Data collection statistics can be found in Table 1.

### Table 1: Data collection and refinement statistics.

<table>
<thead>
<tr>
<th>PDB ID</th>
<th>3ZHP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Space group</td>
<td>P2(_{1})</td>
</tr>
<tr>
<td>No. of molecules in the asymmetric unit</td>
<td>2</td>
</tr>
<tr>
<td>Unit cell dimensions</td>
<td>64.8, 120.3, 98.9</td>
</tr>
<tr>
<td>a, b, c (Å)</td>
<td>90.0, 99.7, 90.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Data collection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beamline</td>
</tr>
<tr>
<td>Resolution range (Å)</td>
</tr>
<tr>
<td>Unique observations</td>
</tr>
<tr>
<td>Average multiplicity</td>
</tr>
<tr>
<td>Complenteness (%)</td>
</tr>
<tr>
<td>R&lt;sub&gt;free&lt;/sub&gt;</td>
</tr>
<tr>
<td>Mean (</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Refinement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resolution range (Å)</td>
</tr>
<tr>
<td>R-value, R&lt;sub&gt;free&lt;/sub&gt;</td>
</tr>
<tr>
<td>r.m.s. deviation from ideal bond length (Å)</td>
</tr>
<tr>
<td>r.m.s. deviation from ideal bond angle (°)</td>
</tr>
<tr>
<td>Ramachandran outliers</td>
</tr>
<tr>
<td>Most favoured</td>
</tr>
</tbody>
</table>

* Values within parentheses refer to the highest resolution shell.

The diffraction data was indexed and integrated using MOSFLM [15] and scaled using SCALA [16]. The structure was solved by molecular replacement using PHASER [17]. The search models used were PDB IDs 3CKW (human MST3) and an ensemble of 3GNI, 1UPK and 2WTK (MO25\( ^{b} \)). Two molecules of the MST3:MO25\( ^{b} \) complex were present in the asymmetric unit. The model was built in Coot [18] and refined with REFMAC5 [19]. Tight NCS restraints were applied during the refinement, which included refinement of TLS parameters.

Further details on general methods and plasmids; Buffers, cell culture, transfection and immunoprecipitation, expression MST3 and kinase activity measurements, expression and purification of MO25 mutants in E. coli is provided in the supplementary section.

3. Results and discussion

3.1. Description of the MST3:MO25 complex

We crystallised a complex of an MST3 catalytic fragment (residues 19–289) with full length MO25\( ^{b} \). The MST3 numbering is given according to that of isoform b (NCBI NP_001027467.2) (Table 1). The 19–289 fragment encompasses the kinase domain, but lacks the C-terminal non-catalytic domain that contains a WIF motif (residues 325–327 in MST3). The equivalent residues in STRAD\( ^{x} \) (WEF: residues 429–431) bind to a C-terminal hydrophobic pocket on MO25\( ^{x} \) [9,20].

Two copies of the MST3:MO25\( ^{b} \) complex occupied the crystallographic asymmetric unit and in each case the same binding arrangement for MST3 and MO25\( ^{b} \) was observed. The domain arrangement resembles that of the previously published complex between STRAD\( ^{x} \) and MO25\( ^{x} \) [10]. MO25\( ^{b} \) binds to MST3 adjacent to the helix \( \chi^{C} \) which has a key role regulating kinase activity in most kinases. Structural comparison with the STRAD\( ^{x} \):MO25\( ^{x} \) complex revealed additional interactions involving MST3 strands β4 and β5 (Fig. 1). These interactions primarily involve three out of the six structural repeats of MO25\( ^{b} \). The residues of MO25\( ^{b} \) that interact with MST3 are highly conserved in both MO25 isoforms (Fig. 2B).

The extensive number of interactions between MST3 and MO25\( ^{b} \) can be divided into three sections: (a) Hydrogen bonding interactions involving the central part of \( \chi^{C} \) and strand β4. There
are hydrogen bonds from the side-chains of Tyr85 and Ser88 to Asp178 of MO25β, as well as between the side-chains of Gln68 and Ser181 of MO25β (Fig. 1E and F). (b) Central hydrophobic interactions involving the N-terminal part of αC and residues from strands β3, β4 and β5. Leu57, Ile64, Leu90, Leu95 from MST3 form this core hydrophobic patch with Phe177 and Val223 from MO25β (Fig. 1E and F). (c) A network of hydrogen bonding interactions involving the loop between MST3 strand β3 and αC of MST3. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Fig. 2. Sequence alignments of (A) Relevant regions of kinases activated by MO25, and (B) MO25 isoforms. Residues of MST3 or MO25β that are on the interface between MST3 and MO25β are marked with a black * above the alignment. Known phosphorylation sites of MST3 are marked with a red *. Full sequence alignments can be seen in the Supplementary material. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
the centre of this network, forming hydrogen bonds to the backbone nitrogen atom of MO25β Asn268 and the side-chain of MO25β Ser266. Additional hydrogen bonds are formed between the side-chains of Asp62 and MO25β Arg226, and between the backbone oxygen of Leu57 and MO25β Tyr222 (Fig. 1C and D).

These results suggest that MO25β activates MST3 by stabilisation of αC in an active position. In inactive kinases it is often possible for αC to assume an outward position, displaced away from the ATP binding site. As MO25β binds to αC and also to β4 and β5 it fixes the position of αC relative to β4, β5 and the rest of the N-terminal lobe of the kinase domain. Therefore the binding energy of MO25β to MST3 is used to pre-organise the catalytically important regions of the kinase domain, a mechanism frequently observed for activators of kinases. The stabilisation of αC also leads to the partial stabilisation of the activation loop via a number of interactions between them, in particular in the region around the DFG motif. However, MST3 will be activated further by auto-phosphorylation on Thr178.

The binding angle between the MST3 kinase domain and MO25β is slightly different to that between STRADα and MO25α (Fig. 3). This difference may be however influenced by differences in crystal packing environment, but it might also be a consequence of the lack of a WEF peptide binding to MO25β. The difference in binding angle does not significantly change the surface area of interaction, or the angle of the key kinase regulatory element helix αC.

3.2. Mutational analysis of interface residues

To assess the importance of the interface residues in mediating the activation of full length MST3 by MO25, we compared basal and MO25-stimulated activity of full length MST3 and the crystallised MST3 (19–289) fragment. The data showed that the full length MST3 was activated by both MO25α and MO25β isoforms as previously reported [20], whilst the crystallised MST3 (19–289) fragment was devoid of catalytic activity and the addition of either MO25α or β did not result in any further activation. A fragment of MST3 that encompasses the WIF motif (i.e. residues 19–319) lacking in the crystallised MST3 displayed similar basal and MO25 induced activity to full length MST3 (Fig. 4A).

The crystal structure of MST3 (19–289) in complex with MO25β was used to design mutations in full length MST3 as well as MO25 isoforms to insight into the residues needed for binding between the two proteins, which result in an increased kinase activity of MST3 by MO25. We first mutated residues on full length MST3 that were implicated to interact with MO25β (Glu58, Ile71, Tyr85, Ser88, and Leu90) and tested how this impacted on the basal MST3 activity and its activation by MO25α. This revealed that mutation of Glu58 or Ile71 to Ala did not affect basal activity but prevented MST3 activation by MO25α. Mutation of Tyr85 to Ala markedly inhibited basal MST3 activity, while mutating Tyr85 to Phe maintained basal activity and partially suppressed activation by MO25α. Mutation of Ser88 and Leu90 markedly reduced basal MST3 activity but the activity of these mutants was still enhanced 2- to 3-fold by MO25α (Fig. 4B). We also mutated a number of residues on MO25α implicated in binding to MST3. This revealed that mutation of MO25α Tyr223 that interacts with MST3 Leu57 abolished activation of MST3 by MO25α, similarly to the previously reported R227A + M260A double mutant [20] (Fig. 4C).

Three of these mutations reduced basal MST3 activity significantly. The aromatic ring of Tyr85 is probably important for stabilisation and binding of strands β4 and β5 against αC, since Y85F retained basal activity compared to Y85A, which reduced basal activity (Fig. 4B). In the case of S88A and L90A, which also reduced basal activity, the same explanation would apply: secure binding of β4 to β5 is presumably important for the stability of the N-terminal lobe. The prevention of MO25 activation by the I71A and E88A mutants shows that, respectively, the central hydrophobic binding interface and the interactions between the β3–αC loop and MO25 are both essential for activation by MO25. The essential nature of the β3–αC loop interactions with MO25 are emphasised by the inability of MO25α Y223A or Y223F to activate MST3.

3.3. Comparison of MST3 activation to OSR1 and SPAK

The kinases OSR1 and SPAK are activated around 25 times more strongly by MO25 than are MST3, MST4 and YSK1. Analysis of the MST3 residues at the interface with MO25β reveals that many of the interacting residues are conserved across all five of these kinases (Fig. 2A). Of the five MST3 residues on β4 and β5, four are completely conserved (Tyr85, Ser88, Leu90) while Leu90 is conservatively substituted by Val in OSR1 and SPAK. Of the six MST3 residues on β3 and αC that interact with MO25β, three are completely conserved (Leu57, Glu58 and Ile71) and two are conservatively substituted in OSR1 and SPAK (Asp62 (as Thr) and Ile64 (as Met)). However, one key difference is Gln68 which is replaced by Leu in OSR1 and SPAK. Gln68 provides a polar side-chain at the centre of an otherwise hydrophobic patch (Fig. 1E and F). Replacement of Gln68 with Leu would significantly increase the interacting surface that stabilizes this hydrophobic interaction. This would presumably increase the affinity of MO25 for OSR1 and SPAK and therefore provide more binding energy for stabilisation of a catalytically active kinase conformation.

There is one other potentially key difference between MST3, MST4 or YSK1, and OSR1 or SPAK, which is that the former all have a WXF motif, while the latter have a WEF motif. STRADα also has a WXF motif like MST3, and the structure of STRADα with MO25α [10] suggests that replacement of WXF with WXW may increase affinity by increasing the hydrophobic interaction area between the WXW motif and MO25α, and possibly providing an additional hydrogen bond to Asn261 of MO25α.

3.4. The C-terminal non-catalytic domain of MST3 is essential for activity

Our results show that the C-terminal non-catalytic region of MST3 is essential for activity, even in the absence of MO25. However, mutation of the Thr and Phe residues in the WIF motif to Ala in full length MST3 or MST4 only reduced basal kinase activity...
3.5. Relevance to activation of MST3 substrates

MST3 has been reported to activate NDR2 protein kinase [23] by phosphorylating the Thr of its hydrophobic motif (sequence FLNYT). Recently it has been reported that in addition to autophosphorylation on Thr178 of its activation loop, MST3 also autophosphorylates on Thr328 which is located just after the WIF motif. It therefore may be that human MO25 would have an activating function for MST3 on NDR, in an evolutionarily conserved mechanism.

**Author contributions**

JME and MS undertook structural studies (Fig. 1), YM undertook functional analysis (Fig. 3) JME, YM, DRA and SK planned the experiments, analysed the experimental data and wrote the manuscript.

**Acknowledgments**

We thank excellent technical support of the MRC-Protein Phosphorylation Unit (PPU) DNA Sequencing Service (coordinated by Nicholas Helps), the MRC-PPU cloning team (coordinated by Mark Peggie and Rachel Toth). This work was supported by the Medical Research Council and the pharmaceutical companies supporting the Division of Signal Transduction Therapy Unit (AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck KgaA, Janssen Pharmaceutica and Pfizer). The Structural Genomics Consortium is a registered charity (number 1097737) that receives funds from the Canadian Institutes for Health Research, the Canada Foundation for Innovation, Genome Canada, GlaxoSmithKline, Pfizer, Eli Lilly, the Novartis Research Foundation, Takeda, Boehringer Ingelheim, the Ontario Ministry of Research and Innovation and the Wellcome Trust. The authors declare no conflict of interest.

**Appendix A. Supplementary data**

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.bbrc.2012.12.113.
References


